Finally, the bone marrow of Rpl22-deficient mice contained ~20% more CD34+ cells (Figure 2D) and an expansion of GMPs (Lin− c-Kit+ CD34+ FCγRhigh; Figure 2E), as is typically observed in patients with higher risk for MDS and AML.30 Here, RPL22 is linked to myelodysplastic syndrome.